Interventional Active not recruiting Phase 3
NCT05614349 on ClinicalTrials.gov
Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings
- Sponsor: Unity Health Toronto
- Collaborators: Health Canada, Canadian Institutes of Health Research (CIHR)
- Enrollment: 797 (Actual)
- Study start: 2023-01-16 (Actual)
- Primary completion: 2025-04-28 (Actual)
- Study completion: 2025-06-28 (Estimated)
- Allocation: Randomized
- InterventionModel: Parallel
- Masking: None
- PrimaryPurpose: Treatment
Brief Summary
CanTreatCOVID is an open-label, individually randomized, multi-centre, national trial. CanTreatCOVID aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges, and outcomes of therapeutics for SARS-CoV-2 for non-hospitalized patients in Canada. Participants will be randomized to receive usual care (i.e. supportive care and symptom relief) or a study therapeutic, which will be determined by the Canadian COVID-19 Out-Patient Therapeutics Committee. The primary outcomes being evaluated is hospitalization and/or death at 28 days, as well as time to recovery.
Conditions
- COVID-19
Intervention / Treatment
- Drug: Paxlovid
- Drug: Antioxidant
Primary Outcome Measures
- All-cause hospitalization or death rate (Day 28)
Countries
Canada
Locations and Investigators
- The Governors of the University of Calgary, Calgary, Canada
- University of British Columbia, Vancouver, Canada
- The University of Manitoba, Winnipeg, Canada
- Eastern Health Newfoundland and Labrador, St. John's, Canada
- Unity Health Toronto, Toronto, Canada
- The Research Institute of the McGill University Health Centre, Montreal, Canada